{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T07:44:52Z","timestamp":1767771892512,"version":"build-2238731810"},"reference-count":63,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI145322"],"award-info":[{"award-number":["AI145322"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.mcna.2025.01.001","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T15:49:59Z","timestamp":1740152999000},"page":"721-734","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Fulminant Clostridioides difficile Infection"],"prefix":"10.1016","volume":"109","author":[{"given":"Jae H.","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmine Y.","family":"Jackson-Akers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook C.","family":"Hoang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian W.","family":"Behm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cirle A.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mcna.2025.01.001_bib1","unstructured":"Centers for Disease Control and Prevention (U.S.), Antibiotic resistance threats in the United States, 2019 [Internet], 2019, Centers for Disease Control and Prevention (U.S.), Available at: https:\/\/stacks.cdc.gov\/view\/cdc\/82532 (Accessed 9 October 2024)."},{"issue":"13","key":"10.1016\/j.mcna.2025.01.001_bib2","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care\u2013associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.mcna.2025.01.001_bib3","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/cis335","article-title":"Burden of Clostridium difficile on the healthcare system","volume":"55","author":"Dubberke","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.001_bib4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.14309\/ajg.0000000000001278","article-title":"ACG clinical guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections","volume":"116","author":"Kelly","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.001_bib5","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the infectious diseases society of America (IDSA) and society for healthcare epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00000658-200203000-00008","article-title":"Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications","volume":"235","author":"Dallal","year":"2002","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.001_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy175","article-title":"Predictors of mortality among a national cohort of veterans with recurrent Clostridium difficile infection","volume":"5","author":"Appaneal","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.mcna.2025.01.001_bib8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.idcr.2017.03.012","article-title":"Clostridium difficile bacteremia: report of two cases in French hospitals and comprehensive review of the literature","volume":"8","author":"Doufair","year":"2017","journal-title":"IDCases"},{"key":"10.1016\/j.mcna.2025.01.001_bib9","doi-asserted-by":"crossref","unstructured":"Granata G, Mariotti D, Ascenzi P, et al. A. High Serum Levels of Toxin A Correlate with Disease Severity in Patients with Clostridioides difficile Infection. Antibiotics 2021, 10, 1093. https:\/\/doi.org\/10.3390\/antibiotics10091093","DOI":"10.3390\/antibiotics10091093"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.001_bib10","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nrmicro.2016.108","article-title":"Clostridium difficile colitis: pathogenesis and host defence","volume":"14","author":"Abt","year":"2016","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mcna.2025.01.001_bib11","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.anaerobe.2015.05.005","article-title":"Leukemoid reaction to Clostridium difficile infection","volume":"34","author":"Naaraayan","year":"2015","journal-title":"Anaerobe"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.001_bib12","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1017\/ice.2015.54","article-title":"Outcomes of Clostridium difficile infection in hospitalized leukemia patients: a nationwide analysis","volume":"36","author":"Luo","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.001_bib13","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/tid.12267","article-title":"Risk factors for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients","volume":"16","author":"Huang","year":"2014","journal-title":"Transpl Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib14","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00180-20","article-title":"Systemic inflammatory mediators are effective biomarkers for predicting adverse outcomes in Clostridioides difficile infection","volume":"11","author":"Dieterle","year":"2020","journal-title":"mBio"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00905-20","article-title":"Immune profiling to predict outcome of Clostridioides difficile infection","volume":"11","author":"Abhyankar","year":"2020","journal-title":"mBio"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/1471-2334-13-148","article-title":"Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy","volume":"13","author":"Miller","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.001_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.bjid.2015.05.005","article-title":"Application of the ATLAS score for evaluating the severity of Clostridium difficile infection in teaching hospitals in Mexico","volume":"19","author":"Hern\u00e1ndez-Garc\u00eda","year":"2015","journal-title":"Braz J Infect Dis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib18","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofu048","article-title":"Determinants of Clostridium difficile infection incidence across diverse United States geographic locations","volume":"1","author":"Lessa","year":"2014","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib19","first-page":"11170","article-title":"Risk factors for postoperative Clostridium difficile infection after radical cystectomy for bladder cancer: a NSQIP database analysis","volume":"29","author":"Prunty","year":"2022","journal-title":"Can J Urol"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jinf.2011.12.003","article-title":"Clostridium difficile infection in HIV-seropositive individuals and transplant recipients","volume":"64","author":"Collini","year":"2012","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.001_bib21","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1007\/s11606-019-04935-6","article-title":"Functional and cognitive status in Clostridium difficile infection in the hospitalized elderly: a retrospective study of two sites","volume":"34","author":"Fernandez-Cotarelo","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.mcna.2025.01.001_bib22","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ajic.2015.03.017","article-title":"Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients","volume":"43","author":"Archbald-Pannone","year":"2015","journal-title":"Am J Infect Control"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib23","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.crohns.2008.09.003","article-title":"Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease","volume":"3","author":"Bossuyt","year":"2009","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1136\/gut.2007.128231","article-title":"Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease","volume":"57","author":"Ananthakrishnan","year":"2008","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib25","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1093\/ecco-jcc\/jjw117","article-title":"Incidence and outcome of Clostridium difficile infection in hospitalized patients with inflammatory bowel disease in the UK","volume":"11","author":"Joshi","year":"2017","journal-title":"J Crohns Colitis"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib26","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.sla.0000236628.79550.e5","article-title":"Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain","volume":"245","author":"Lamontagne","year":"2007","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib27","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/TA.0000000000000105","article-title":"Fulminant Clostridium difficile colitis: prospective development of a risk scoring system","volume":"76","author":"van der Wilden","year":"2014","journal-title":"J Trauma Acute Care Surg"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib28","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz552","article-title":"Eosinopenia and binary toxin increase mortality in hospitalized patients with Clostridioides difficile infection","volume":"7","author":"Carlson","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.001_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106118","article-title":"Calprotectin and lactoferrin faecal levels in patients with Clostridium difficile infection (CDI): a prospective cohort study","volume":"9","author":"Swale","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.mcna.2025.01.001_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s10096-013-2043-1","article-title":"Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality","volume":"33","author":"Boone","year":"2014","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"16","key":"10.1016\/j.mcna.2025.01.001_bib31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12879-016-1618-8","article-title":"Correlation between fecal calprotectin levels, disease severity and the hypervirulent ribotype 027 strain in patients with Clostridium difficile infection","volume":"309","author":"Peretz","year":"2016","journal-title":"BMC Infect Dis"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.001_bib32","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s15010-013-0473-4","article-title":"The impact of pseudomembrane formation on the outcome of Clostridium difficile-associated disease","volume":"41","author":"Berdichevski","year":"2013","journal-title":"Infection"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1086\/658336","article-title":"Comparison of clinical severity score indices for Clostridium difficile infection","volume":"32","author":"Fujitani","year":"2011","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.001_bib34","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jinf.2017.12.001","article-title":"Potential of real-time PCR threshold cycle (CT) to predict presence of free toxin and clinically relevant C. difficile infection (CDI) in patients with cancer","volume":"76","author":"Kamboj","year":"2018","journal-title":"J Infect"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.001_bib35","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1177\/2050640617750809","article-title":"Clostridium difficile fecal toxin level is associated with disease severity and prognosis","volume":"6","author":"Cohen","year":"2018","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.mcna.2025.01.001_bib36","article-title":"Ultrasensitive and quantitative toxin measurement correlates with baseline severity, severe outcomes, and recurrence among hospitalized patients with Clostridioides difficile infection","volume":"19","author":"Alonso","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.001_bib37","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1017\/ice.2015.187","article-title":"In the endemic setting, Clostridium difficile ribotype 027 is virulent but not hypervirulent","volume":"36","author":"Aitken","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.001_bib38","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/cid\/cit127","article-title":"Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection","volume":"56","author":"Walker","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.001_bib39","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cmi.2019.09.004","article-title":"The recent emergence of a highly related virulent Clostridium difficile clade with unique characteristics","volume":"26","author":"Shaw","year":"2020","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib40","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41467-020-20793-x","article-title":"Host immunity modulates the efficacy of microbiota transplantation for treatment of Clostridioides difficile infection","volume":"12","author":"Littmann","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.mcna.2025.01.001_bib41","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.001_bib42","doi-asserted-by":"crossref","first-page":"422","DOI":"10.14740\/jocmr2117w","article-title":"Vancomycin enemas as adjunctive therapy for Clostridium difficile infection","volume":"7","author":"Malamood","year":"2015","journal-title":"J Clin Med Res"},{"key":"10.1016\/j.mcna.2025.01.001_bib43","article-title":"Dose addition of intravenous metronidazole to oral vancomycin improve outcomes in Clostridioides difficile infection?","volume":"12","author":"Wang","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.001_bib44","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1001\/jamainternmed.2016.9045","article-title":"Comparative effectiveness of vancomycin and metronidazole for the prevention of recurrence and death in patients with Clostridium difficile infection","volume":"177","author":"Stevens","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.001_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2015\/934594","article-title":"Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection","volume":"26","author":"Zhanel","year":"2015","journal-title":"Can J Infect Med Microbiol"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.001_bib46","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmi.2018.12.007","article-title":"Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study","volume":"25","author":"Gentry","year":"2019","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.001_bib47","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ijantimicag.2013.01.020","article-title":"All-cause mortality imbalance in the tigecycline phase 3 and 4 clinical trials","volume":"41","author":"McGovern","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.mcna.2025.01.001_bib48","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.001_bib49","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1007\/s10096-019-03756-z","article-title":"Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence","volume":"39","author":"Kechagias","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"10.1016\/j.mcna.2025.01.001_bib50","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00001-22","article-title":"Impact of tigecycline on C. difficile outcomes: case series and propensity-matched retrospective study","volume":"66","author":"Phillips","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"9251","key":"10.1016\/j.mcna.2025.01.001_bib51","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(00)03592-3","article-title":"Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea","volume":"357","author":"Kyne","year":"2001","journal-title":"Lancet"},{"issue":"4 Pt 1","key":"10.1016\/j.mcna.2025.01.001_bib52","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3476(05)83393-1","article-title":"Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin","volume":"118","author":"Leung","year":"1991","journal-title":"J Pediatr"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib53","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajic.2006.06.007","article-title":"Clinical outcomes of intravenous immune globulin in severe clostridium difficile-associated diarrhea","volume":"35","author":"Juang","year":"2007","journal-title":"Am J Infect Control"},{"issue":"4","key":"10.1016\/j.mcna.2025.01.001_bib54","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.mcna.2025.01.001_bib55","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1002\/bjs.8868","article-title":"West Midlands Research Collaborative. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis","volume":"99","author":"Bhangu","year":"2012","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.mcna.2025.01.001_bib56","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1007\/s11605-009-0819-5","article-title":"Long-term follow-up of patients with fulminant Clostridium difficile colitis","volume":"13","author":"Miller","year":"2009","journal-title":"J Gastrointest Surg"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib57","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/SLA.0b013e31822ade48","article-title":"Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease","volume":"254","author":"Neal","year":"2011","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.mcna.2025.01.001_bib58","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.amjsurg.2018.09.023","article-title":"No survival advantage exists for patients undergoing loop ileostomy for clostridium difficile colitis","volume":"217","author":"Hall","year":"2019","journal-title":"Am J Surg"},{"key":"10.1016\/j.mcna.2025.01.001_bib59","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/apt.13290","article-title":"Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate","volume":"42","author":"Fischer","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.001_bib60","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.cgh.2019.12.029","article-title":"Fecal microbiota transplant decreases mortality in patients with refractory severe or fulminant Clostridioides difficile infection","volume":"18","author":"Cheng","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.mcna.2025.01.001_bib61","doi-asserted-by":"crossref","first-page":"695","DOI":"10.7326\/M18-3635","article-title":"Incidence of bloodstream infections, length of hospital stay, and survival in patients with recurrent Clostridioides difficile infection treated with fecal microbiota transplantation or antibiotics: a prospective cohort study","volume":"171","author":"Ianiro","year":"2019","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.mcna.2025.01.001_bib62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/19490976.2016.1273998","article-title":"Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: a promising treatment approach","volume":"8","author":"Fischer","year":"2017","journal-title":"Gut Microb"},{"issue":"2","key":"10.1016\/j.mcna.2025.01.001_bib63","article-title":"Hospitalized older patients with Clostridioides difficile infection refractory to conventional antibiotic therapy benefit from fecal microbiota transplant","volume":"3","author":"Shin","year":"2021","journal-title":"Adv Geriatr Med Res"}],"updated-by":[{"DOI":"10.1016\/j.mcna.2025.10.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000}}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000112?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712525000112?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:50:55Z","timestamp":1763754655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712525000112"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0025712525000112"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.001","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fulminant Clostridioides difficile Infection","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2025.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}